These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 18566816)

  • 1. Does 18F-FDG PET/CT add diagnostic accuracy in incidentally identified non-secreting adrenal tumours?
    Tessonnier L; Sebag F; Palazzo FF; Colavolpe C; De Micco C; Mancini J; Conte-Devolx B; Henry JF; Mundler O; Taïeb D
    Eur J Nucl Med Mol Imaging; 2008 Nov; 35(11):2018-25. PubMed ID: 18566816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidental non-secreting adrenal masses in cancer patients: intra-individual comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography with computed tomography and shift magnetic resonance imaging.
    Gratz S; Kemke B; Kaiser W; Heinis J; Behr TM; Höffken H
    J Int Med Res; 2010; 38(2):633-44. PubMed ID: 20515577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What parameters from 18F-FDG PET/CT are useful in evaluation of adrenal lesions?
    Kunikowska J; Matyskiel R; Toutounchi S; Grabowska-Derlatka L; Koperski L; Królicki L
    Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2273-80. PubMed ID: 25027709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
    Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
    Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG-PET/CT and FLT-PET/CT for differentiating between lipid-poor benign and malignant adrenal tumours.
    Nakajo M; Jinguji M; Fukukura Y; Kajiya Y; Tani A; Nakajo M; Nakabeppu Y; Arimura H; Nishio Y; Nakamura F; Yoshiura T
    Eur Radiol; 2015 Dec; 25(12):3696-705. PubMed ID: 25925356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Use of 18F-FDG-positron emission tomography in presurgical evaluation of nonspecific or suspectious adrenal masses in non-oncologic patients].
    Pavón-Paz I; Rosado-Sierra JA; Balsa-Bretón MÁ; Guijarro-Armas G; Merino-Viveros M; Penín-Gonzalez FJ
    Med Clin (Barc); 2016 Feb; 146(3):104-7. PubMed ID: 26343158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of adrenal masses by 18F-FDG positron emission tomography scanning.
    Han SJ; Kim TS; Jeon SW; Jeong SJ; Yun M; Rhee Y; Kang ES; Cha BS; Lee EJ; Lee HC; Lim SK
    Int J Clin Pract; 2007 May; 61(5):802-9. PubMed ID: 17343665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study.
    Guerin C; Pattou F; Brunaud L; Lifante JC; Mirallié E; Haissaguerre M; Huglo D; Olivier P; Houzard C; Ansquer C; Hindié E; Loundou A; Archange C; Tabarin A; Sebag F; Baumstarck K; Taïeb D
    J Clin Endocrinol Metab; 2017 Jul; 102(7):2465-2472. PubMed ID: 28431167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current generation time-of-flight (18)F-FDG PET/CT provides higher SUVs for normal adrenal glands, while maintaining an accurate characterization of benign and malignant glands.
    Koopman D; van Dalen JA; Stigt JA; Slump CH; Knollema S; Jager PL
    Ann Nucl Med; 2016 Feb; 30(2):145-52. PubMed ID: 26644009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FDG PET/CT in the characterization and surgical decision concerning adrenal masses: a prospective multicentre evaluation.
    Ansquer C; Scigliano S; Mirallié E; Taïeb D; Brunaud L; Sebag F; Leux C; Drui D; Dupas B; Renaudin K; Kraeber-Bodéré F
    Eur J Nucl Med Mol Imaging; 2010 Aug; 37(9):1669-78. PubMed ID: 20490488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic performance of unenhanced computed tomography and
    Delivanis DA; Bancos I; Atwell TD; Schmit GD; Eiken PW; Natt N; Erickson D; Maraka S; Young WF; Nathan MA
    Clin Endocrinol (Oxf); 2018 Jan; 88(1):30-36. PubMed ID: 28815667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FDG PET/CT in the evaluation of adrenal masses in lung cancer patients.
    Lu Y; Xie D; Huang W; Gong H; Yu J
    Neoplasma; 2010; 57(2):129-34. PubMed ID: 20099976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
    Ciftci E; Turgut B; Cakmakcilar A; Erturk SA
    Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of lipid-rich adrenal tumors by FDG PET/CT: Are they hormone-secreting or not?
    Takanami K; Kaneta T; Morimoto R; Satoh F; Nakamura Y; Takase K; Takahashi S
    Ann Nucl Med; 2014 Feb; 28(2):145-53. PubMed ID: 24272068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients.
    Boland GW; Blake MA; Holalkere NS; Hahn PF
    AJR Am J Roentgenol; 2009 Apr; 192(4):956-62. PubMed ID: 19304700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk stratification of adrenal masses by [
    Salgues B; Guerin C; Amodru V; Pattou F; Brunaud L; Lifante JC; Mirallié E; Sahakian N; Castinetti F; Loundou A; Baumstarck K; Sebag F; Taïeb D
    Clin Endocrinol (Oxf); 2021 Feb; 94(2):133-140. PubMed ID: 32978795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG PET/CT in the evaluation of adrenal masses.
    Metser U; Miller E; Lerman H; Lievshitz G; Avital S; Even-Sapir E
    J Nucl Med; 2006 Jan; 47(1):32-7. PubMed ID: 16391184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - a multicenter experience.
    Cistaro A; Niccoli Asabella A; Coppolino P; Quartuccio N; Altini C; Cucinotta M; Alongi P; Balma M; Sanfilippo S; Buschiazzo A; Piccardo A; Fanelli M; Sambuceti G; Bomanji J; Baldari S; Bisi G; Fanti S; Rubini G
    Hell J Nucl Med; 2015; 18(2):97-102. PubMed ID: 26187207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI.
    Yun M; Kim W; Alnafisi N; Lacorte L; Jang S; Alavi A
    J Nucl Med; 2001 Dec; 42(12):1795-9. PubMed ID: 11752075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.